Literature DB >> 23648634

Prognostic utility of biochemical markers of cardiovascular risk: impact of biological variability.

Kristine S Alexander, Steven C Kazmierczak, Caryn K Snyder, Jon A Oberdorf, David H Farrell.   

Abstract

BACKGROUND: Although a variety of biochemical markers are used to help predict the risk of cardiovascular disease, the prognostic utility of any marker used as a risk assessment tool is dependent on the long- and short-term biological variability that the marker shows in different individuals.
METHODS: We measured total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol; triglycerides; high-sensitivity C-reactive protein (hsCRP); total fibrinogen; and γ' fibrinogen in blood samples collected from 15 apparently healthy individuals over the course of 1 year. Repeated measures variation estimates were used to calculate short- and long-term intraclass correlation coefficients (ICC), within- and between-subject coefficients of variation (CVI and CVG, respectively), validity coefficients, and indices of individuality for each marker.
RESULTS: HDL cholesterol demonstrated the lowest variability profile, with an ICC of 0.84 and CVI of 11.1 (95% CI: 8.3, 17.0). hsCRP showed the highest levels of short- and long-term within-subject variability [CVI (95% CI): 54.8 (32.8, 196.3) and 77.1 (53.3, 141.3), respectively]. Stated differently, it would require five separate measurements of hsCRP, performed on samples collected over multiple days, to provide the risk assessment information provided by a single measurement of HDL cholesterol. γ' Fibrinogen demonstrated an ICC of 0.79 and CVI of 14.3 (95% CI: 10.6, 21.9).
CONCLUSIONS: hsCRP showed very high biological variability, such that a single measurement of hsCRP lacks sufficient clinical utility to justify routine measurement. The variability profile of γ' fibrinogen was not markedly different than HDL cholesterol, necessitating only a limited number of measurements to establish an individual's risk of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23648634      PMCID: PMC4117345          DOI: 10.1515/cclm-2012-0750

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  26 in total

1.  Assessment of genetic determinants of the association of γ' fibrinogen in relation to cardiovascular disease.

Authors:  Rehana S Lovely; Qiong Yang; Joseph M Massaro; Jing Wang; Ralph B D'Agostino; Christopher J O'Donnell; Jackilen Shannon; David H Farrell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-14       Impact factor: 8.311

2.  Effect of freezing method and storage at -20 degrees C and -70 degrees C on prothrombin time, aPTT and plasma fibrinogen levels.

Authors:  Sonja Alesci; Martin Borggrefe; Carl-Erik Dempfle
Journal:  Thromb Res       Date:  2009-01-06       Impact factor: 3.944

3.  Elevated fibrinogen gamma' ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome.

Authors:  Elim Y L Cheung; Hans L Vos; Marieke J H A Kruip; Heleen M den Hertog; J Wouter Jukema; Moniek P M de Maat
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113

4.  Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.

Authors:  Maryam Kavousi; Suzette Elias-Smale; Joost H W Rutten; Maarten J G Leening; Rozemarijn Vliegenthart; Germaine C Verwoert; Gabriel P Krestin; Matthijs Oudkerk; Moniek P M de Maat; Frank W G Leebeek; Francesco U S Mattace-Raso; Jan Lindemans; Albert Hofman; Ewout W Steyerberg; Aad van der Lugt; Anton H van den Meiracker; Jacqueline C M Witteman
Journal:  Ann Intern Med       Date:  2012-03-20       Impact factor: 25.391

5.  Differential regulation of fibrinogen γ chain splice isoforms by interleukin-6.

Authors:  Chantelle M Rein-Smith; Nathan W Anderson; David H Farrell
Journal:  Thromb Res       Date:  2012-10-01       Impact factor: 3.944

6.  Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?

Authors:  James P McCormack; G Michael Allan
Journal:  PLoS Med       Date:  2010-02-02       Impact factor: 11.069

7.  Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.

Authors:  Mark A Hlatky; Philip Greenland; Donna K Arnett; Christie M Ballantyne; Michael H Criqui; Mitchell S V Elkind; Alan S Go; Frank E Harrell; Yuling Hong; Barbara V Howard; Virginia J Howard; Priscilla Y Hsue; Christopher M Kramer; Joseph P McConnell; Sharon-Lise T Normand; Christopher J O'Donnell; Sidney C Smith; Peter W F Wilson
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

8.  Pharmacokinetics and safety of fibrinogen concentrate.

Authors:  M J Manco-Johnson; D Dimichele; G Castaman; S Fremann; S Knaub; U Kalina; F Peyvandi; G Piseddu; P Mannucci
Journal:  J Thromb Haemost       Date:  2009-10-05       Impact factor: 5.824

Review 9.  Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts.

Authors:  Tina Shah; Juan P Casas; Jackie A Cooper; Ioanna Tzoulaki; Reecha Sofat; Valerie McCormack; Liam Smeeth; John E Deanfield; Gordon D Lowe; Ann Rumley; F Gerald R Fowkes; Steve E Humphries; Aroon D Hingorani
Journal:  Int J Epidemiol       Date:  2008-10-17       Impact factor: 7.196

10.  C-reactive protein, fibrinogen, and cardiovascular disease prediction.

Authors:  Stephen Kaptoge; Emanuele Di Angelantonio; Lisa Pennells; Angela M Wood; Ian R White; Pei Gao; Matthew Walker; Alexander Thompson; Nadeem Sarwar; Muriel Caslake; Adam S Butterworth; Philippe Amouyel; Gerd Assmann; Stephan J L Bakker; Elizabeth L M Barr; Elizabeth Barrett-Connor; Emelia J Benjamin; Cecilia Björkelund; Hermann Brenner; Eric Brunner; Robert Clarke; Jackie A Cooper; Peter Cremer; Mary Cushman; Gilles R Dagenais; Ralph B D'Agostino; Rachel Dankner; George Davey-Smith; Dorly Deeg; Jacqueline M Dekker; Gunnar Engström; Aaron R Folsom; F Gerry R Fowkes; John Gallacher; J Michael Gaziano; Simona Giampaoli; Richard F Gillum; Albert Hofman; Barbara V Howard; Erik Ingelsson; Hiroyasu Iso; Torben Jørgensen; Stefan Kiechl; Akihiko Kitamura; Yutaka Kiyohara; Wolfgang Koenig; Daan Kromhout; Lewis H Kuller; Debbie A Lawlor; Tom W Meade; Aulikki Nissinen; Børge G Nordestgaard; Altan Onat; Demosthenes B Panagiotakos; Bruce M Psaty; Beatriz Rodriguez; Annika Rosengren; Veikko Salomaa; Jussi Kauhanen; Jukka T Salonen; Jonathan A Shaffer; Steven Shea; Ian Ford; Coen D A Stehouwer; Timo E Strandberg; Robert W Tipping; Alberto Tosetto; Sylvia Wassertheil-Smoller; Patrik Wennberg; Rudi G Westendorp; Peter H Whincup; Lars Wilhelmsen; Mark Woodward; Gordon D O Lowe; Nicholas J Wareham; Kay-Tee Khaw; Naveed Sattar; Chris J Packard; Vilmundur Gudnason; Paul M Ridker; Mark B Pepys; Simon G Thompson; John Danesh
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

View more
  3 in total

1.  Multiplexing and Beyond in Biobehavioral Research.

Authors:  Paul J Mills; Christine T Peterson
Journal:  Psychosom Med       Date:  2016 Jul-Aug       Impact factor: 4.312

2.  Ovarian Cancer Risk in Relation to Blood Cholesterol and Triglycerides.

Authors:  Britton Trabert; Cassandra A Hathaway; Megan S Rice; Eric B Rimm; Patrick M Sluss; Kathryn L Terry; Oana A Zeleznik; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-08-17       Impact factor: 4.090

3.  Atomic force microscopy as a tool to evaluate the risk of cardiovascular diseases in patients.

Authors:  Ana Filipa Guedes; Filomena A Carvalho; Inês Malho; Nuno Lousada; Luís Sargento; Nuno C Santos
Journal:  Nat Nanotechnol       Date:  2016-05-16       Impact factor: 39.213

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.